NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67 ...

Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered ...

By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...

Novavax (NVAX) stock jumps as the company beats with its Q4 2025 revenue and records full-year profitability. Read more here.

Novavax has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties.

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 24.4% in the morning session after the company reported fourth-quarter financial results that significantly beat analyst ...

Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 ...

Novavax Inc. shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.

Novavax (NVAX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is ...

Shares of Novavax soared after the company swung to an unexpected profit in the fourth quarter and exceeded its expense-reduction goals. The stock leapt 16% to $11.03 in Thursday afternoon trading, ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had net income of 11 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by ...